Skip to main content
Xvivo Perfusion logo

Xvivo Perfusion — Investor Relations & Filings

Ticker · XVIVO ISIN · SE0004840718 LEI · 549300G2464FYLS14B41 ST Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2018-06-29 Share Issue/Capital Cha…
Country SE Sweden
Listing ST XVIVO

About Xvivo Perfusion

https://www.xvivogroup.com/

Xvivo Perfusion is a medical technology company specializing in ex-vivo organ preservation for transplantation. The company develops machine perfusion technologies, solutions, and services designed to extend the life of major organs, including lungs, livers, and kidneys. Its core technology, organ perfusion, is an alternative to static cold storage that continuously supplies an organ with an oxygenated solution while it is outside the body. This process helps support cellular function, prevent tissue damage, and allows clinicians to assess organ viability prior to transplant. The company's objective is to increase organ utilization, extend preservation times, and improve patient outcomes. Key products include the XPS™ for lung perfusion, Liver Assist™, Kidney Assist Transport™, and the PERFADEX® Plus solution for lung preservation.

Recent filings

Filing Released Lang Actions
Förändring av antalet aktier och röster i XVIVO Perfusion
Share Issue/Capital Change Classification · 98% confidence The document is a press release dated June 29, 2018, announcing a change in the total number of shares and votes due to the exercise of stock options. Specifically, it states that the number of shares increased by 212,000, resulting in a new total of 26,402,496 shares as of that date. This directly relates to a change in the company's capital structure (share count). Reviewing the definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate category for announcements detailing changes in the number of outstanding shares. It is not a general earnings release (ER), a dividend notice (DIV), or a director's dealing (DIRS).
2018-06-29 Swedish
XVIVO Perfusion ändrar datum för rapportering av delårsrapport januari – juni 2018 till den 20 juli 2018
Report Publication Announcement Classification · 99% confidence The document is a short press release (1845 characters) dated June 14, 2018, announcing a change in the reporting date for the interim report (delårsrapport) covering January–June 2018, moving it to July 20, 2018. This is not the report itself, but an announcement about the timing of a future report release. According to Rule 2, if a document is short and announces the publication/timing of a report, it should be classified as a Report Publication Announcement (RPA).
2018-06-14 Swedish
XVIVO Perfusion changes the date of reporting of the interim report January - June 2018 to July 20, 2018
Report Publication Announcement Classification · 99% confidence The document is a short press release dated June 14, 2018, announcing a change in the reporting date for the 'interim report January - June 2018' to July 20, 2018. This document is not the interim report itself, but an announcement about the publication schedule of a future report. According to Rule 2 ('MENU VS MEAL' rule), a short announcement regarding the timing or release of a report points towards 'Report Publication Announcement' (RPA). It is not a general regulatory filing (RNS) because it fits the specific RPA definition better.
2018-06-14 English
UNITED THERAPEUTICS OCH XVIVO PERFUSION INLEDER SAMARBETE FÖR ATT MINSKA ORGANBRISTEN GENOM UTÖKAD TJÄNST INOM ORGANUTVÄRDERING
Regulatory Filings Classification · 95% confidence The document is titled "Pressmeddelande" (Press Release) and announces a strategic collaboration between United Therapeutics and XVIVO Perfusion regarding organ evaluation technology. It includes specific dates (June 12, 2018), quotes from executives, and detailed information about the technology (XPS™, EVLP). Crucially, the final paragraph states: "Denna information är sådan information som Xvivo Perfusion AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." (This information is such information that Xvivo Perfusion AB (publ) is obliged to disclose pursuant to the EU's Market Abuse Regulation.) This indicates a mandatory regulatory disclosure, but it is not a standard SEC filing like 10-K or ER. Since it is a general regulatory announcement that doesn't fit the specific categories (like DIV, CAP, MANG, etc.), the most appropriate fallback category for a mandatory, non-standard regulatory announcement, especially one originating from a European entity referencing MAR, is Regulatory Filings (RNS). The document length (7281 chars) is substantial enough that it is the primary announcement itself, not just a notice of publication (RPA).
2018-06-12 Swedish
UNITED THERAPEUTICS AND XVIVO PERFUSION ANNOUNCE COLLABORATION TO REDUCE ORGAN SHORTAGE THROUGH EXPANSION OF ORGAN EVALUATION SERVICE
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "Press release" announcing a collaboration between United Therapeutics and XVIVO Perfusion regarding organ evaluation technology. It details a business agreement, product information (XPS), regulatory status (FDA PMA submission, HDE approval), and includes forward-looking statements referencing SEC filings (10-K, 10-Q, 8-K). This content structure—a press release announcing strategic business developments and operational updates, rather than a formal regulatory filing like a 10-K or an earnings report—is characteristic of a general corporate announcement. Since there is no specific category for a general business press release announcing a partnership, and it is not an earnings release (ER), a capital event (CAP), or a management change (MANG), the most appropriate fallback category is Regulatory Filings (RNS), which often serves as the catch-all for significant, non-standard corporate news releases that are mandated for public disclosure, especially given the final line referencing EU Market Abuse Regulation disclosure requirements.
2018-06-12 English
XVIVO Perfusion launches Perfadex Plus, an upgraded ready to use version of Perfadex
Earnings Release Classification · 99% confidence The document is explicitly labeled as a "Press release" announcing a new product launch ("Perfadex Plus") and associated patent filing. It details a business development (product upgrade and launch strategy) rather than providing periodic financial results (ER, IR, 10-K), management changes (MANG), or shareholder voting information (DVA, AGM-R). Since it is a general announcement of a significant business event that doesn't fit into the specific financial or governance categories, it falls best under the general regulatory announcement category, which is RNS (Regulatory Filings), as it is information the company is obliged to make public pursuant to the EU Market Abuse Regulation. FY 2018
2018-06-05 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.